BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lundquist LM, Cole SW, Sikes ML. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop 2014; 5(4): 504-511 [PMID: 25232526 DOI: 10.5312/wjo.v5.i4.504]
URL: https://www.wjgnet.com/2218-5836/full/v5/i4/504.htm
Number Citing Articles
1
Hong-Yu Yuan, Xiao-Lan Zhang, Xue-Hui Zhang, Ling Meng, Ji-Fu Wei. Analysis of patents on anti-rheumatoid arthritis therapies issued in ChinaExpert Opinion on Therapeutic Patents 2015; 25(8): 909 doi: 10.1517/13543776.2015.1044972
2
Hideki Shimaoka, Shinsuke Takeno, Kenji Maki, Takahide Sasaki, Suguru Hasegawa, Yuichi Yamashita. A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancerOncology Letters 2017; 14(3): 3019 doi: 10.3892/ol.2017.6473
3
Selvaraj G. Nataraja, Henry N. Yu, Stephen S. Palmer. Discovery and Development of Small Molecule Allosteric Modulators of Glycoprotein Hormone ReceptorsFrontiers in Endocrinology 2015; 6 doi: 10.3389/fendo.2015.00142
4
Norma Elizabeth Vázquez-Herrera, Antonella Tosti. Current and future pharmacotherapy for alopecia areataExpert Opinion on Orphan Drugs 2015; 3(4): 419 doi: 10.1517/21678707.2015.1021778
5
Xiao Wu, Xuefang Zeng, Lei Wang, Taijun Hang, Min Song. Identification of related substances in tofacitinib citrate by LC-MS techniques for synthetic process optimizationJournal of Pharmaceutical and Biomedical Analysis 2017; 143: 17 doi: 10.1016/j.jpba.2017.05.012
6
Sherihan Salaheldin Abdelhamid Ibrahim, Kristiina M. Huttunen. Orchestrated modulation of rheumatoid arthritis via crosstalking intracellular signaling pathwaysInflammopharmacology 2021; 29(4): 965 doi: 10.1007/s10787-021-00800-3
7
Sarah Benton, Ronda Farah, Rebecca Freese, Maria Hordinsky. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective reviewDermatologic Therapy 2022; 35(4) doi: 10.1111/dth.15310
8
Hart S. Dengler, Xiumin Wu, Ivan Peng, Cornelia H. Rinderknecht, Youngsu Kwon, Eric Suto, Pawan Bir Kohli, Marya Liimatta, Kathy Barrett, Julia Lloyd, Gary Cain, Mike Briggs, Stephanie Addo, Gary Salmon, Savita Ubhayakar, Gauri Deshmukh, Sheerin K. Shahidi-Latham, Cristine M. Quiason-Huynh, Janet Jackman, John Liu, Nicholas C. Ray, Simon C. Goodacre, Adam Johnson, Brent S. McKenzie, Wyne P. Lee, Mark Zak, Jane R. Kenny, Nico Ghilardi. Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthmaScience Translational Medicine 2018; 10(468) doi: 10.1126/scitranslmed.aao2151
9
Shivaprasad Venkatesha, Steven Dudics, Bodhraj Acharya, Kamal Moudgil. Cytokine-Modulating Strategies and Newer Cytokine Targets for Arthritis TherapyInternational Journal of Molecular Sciences 2014; 16(1): 887 doi: 10.3390/ijms16010887
10
Christina M. Rollings, Linda V. Sinclair, Hugh J. M. Brady, Doreen A. Cantrell, Sarah H. Ross. Interleukin-2 shapes the cytotoxic T cell proteome and immune environment–sensing programsScience Signaling 2018; 11(526) doi: 10.1126/scisignal.aap8112
11
Yanmei Li, Yonghua Sun, Shitong Wei, Luyang Zhang, Shihua Zong. Development and evaluation of tofacitinib transdermal system for the treatment of rheumatoid arthritis in ratsDrug Development and Industrial Pharmacy 2021; 47(6): 878 doi: 10.1080/03639045.2021.1916521
12
Bálint Botz, Kata Bölcskei, Zsuzsanna Helyes. Challenges to develop novel anti‐inflammatory and analgesic drugsWIREs Nanomedicine and Nanobiotechnology 2017; 9(3) doi: 10.1002/wnan.1427
13
Robert Harrington, Shamma Ahmad Al Nokhatha, Richard Conway. <p>JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data</p>Journal of Inflammation Research 2020; : 519 doi: 10.2147/JIR.S219586
14
Thales R. Hein, Leonardo Peterson, Barbara J. Bartikoski, Juliana Portes, Rafaela C. Espírito Santo, Ricardo M. Xavier. The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysisArthritis Research & Therapy 2022; 24(1) doi: 10.1186/s13075-022-02858-y
15
G C Nicholson, R A Holloway, B R Leaker, I Kilty, M Salganik, L Tan, P J Barnes, L E Donnelly. A novel flow cytometric-based method to measure kinase inhibition in sputum from COPD subjectsBMJ Open Respiratory Research 2016; 3(1): e000140 doi: 10.1136/bmjresp-2016-000140
16
Licia Maria Henrique da Mota, Bóris Afonso Cruz, Cleandro Pires de Albuquerque, Deborah Pereira Gonçalves, Ieda Maria Magalhães Laurindo, Ivanio Alves Pereira, Jozélio Freire de Carvalho, Geraldo da Rocha Castelar Pinheiro, Manoel Barros Bertolo, Maria Raquel da Costa Pinto, Paulo Louzada‐Junior, Ricardo Machado Xavier, Rina Dalva Neubarth Giorgi, Rodrigo Aires Corrêa Lima. Posicionamento sobre o uso de tofacitinibe no algoritmo do Consenso 2012da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoideRevista Brasileira de Reumatologia 2015; 55(6): 512 doi: 10.1016/j.rbr.2015.08.004
17
Rania T. Malatani, Sana Bilal, Asif Mahmood, Rai Muhammad Sarfraz, Nadiah Zafar, Hira Ijaz, Umaira Rehman, Shehla Akbar, Hala M. Alkhalidi, Heba A. Gad. Development of Tofacitinib Loaded pH-Responsive Chitosan/Mucin Based Hydrogel Microparticles: In-Vitro Characterization and Toxicological ScreeningGels 2023; 9(3): 187 doi: 10.3390/gels9030187
18
Séverine Vermeire, Stefan Schreiber, Robert Petryka, Tanja Kuehbacher, Xavier Hebuterne, Xavier Roblin, Maria Klopocka, Adrian Goldis, Maria Wisniewska-Jarosinska, Andrey Baranovsky, Robert Sike, Kremena Stoyanova, Chantal Tasset, Annegret Van der Aa, Pille Harrison. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trialThe Lancet 2017; 389(10066): 266 doi: 10.1016/S0140-6736(16)32537-5
19
Murat Erdağ, Mehmet Balbaba, Nevin İlhan, İlknur Çalık, Fatih Ulaş, Yesari Eröksüz, Hakan Yıldırım. Protective effect of filgotinib in rat endotoxin-induced uveitis modelInternational Ophthalmology 2021; 41(8): 2905 doi: 10.1007/s10792-021-01851-9
20
Huaxun Wu, Shangxue Yan, Jingyu Chen, Xuexia Luo, Peipei Li, Xiaoyi Jia, Xing Dai, Chun Wang, Qiong Huang, Lihua Liu, Yunfang Zhang, Aiwu Zhou, Yan Chang, LingLing Zhang, Wei Wei. JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cellsJoint Bone Spine 2016; 83(5): 525 doi: 10.1016/j.jbspin.2015.09.002
21
Arezoo Hosseini, Tohid Gharibi, Faroogh Marofi, Mahsa Javadian, Zohreh Babaloo, Behzad Baradaran. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesJournal of Cellular Physiology 2020; 235(9): 5903 doi: 10.1002/jcp.29593
22
Walter Conca, Ihab Weheba, Mohei-Eldin Abouzied, Abeer Abdelsayed, Yousif Aleyouni, Eid Al‐Mutairy, Nasir Bakshi, Mohammad Khalid. Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case ReportFrontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.585761
23
Michael E. Weinblatt, Iain B. McInnes, Joel M. Kremer, Pedro Miranda, Jiri Vencovsky, Xiang Guo, Wendy I. White, Patricia C. Ryan, Alex Godwood, Marius Albulescu, David Close, Gerd R. Burmester. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid ArthritisArthritis & Rheumatology 2018; 70(1): 49 doi: 10.1002/art.40323
24
Feng Huang, Zu-chun Luo. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trialsClinical Rheumatology 2019; 38(2): 523 doi: 10.1007/s10067-018-4299-4
25
Marta Madej, Patryk Woytala, Marek Frankowski, Łukasz Lubiński, Renata Sokolik, Agata Sebastian, Beata Maciążek-Chyra, Piotr Wiland. Tofacitinib in the treatment of active rheumatoid arthritis – single-centre experienceRheumatology 2019; 57(4): 192 doi: 10.5114/reum.2019.87609
26
Young Ho Lee, Sang-Cheol Bae, Gwan Gyu Song. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trialsRheumatology International 2015; 35(12): 1965 doi: 10.1007/s00296-015-3291-4
27
Selvaraj Nataraja, Venkataraman Sriraman, Stephen Palmer. Allosteric Regulation of the Follicle-Stimulating Hormone ReceptorEndocrinology 2018; 159(7): 2704 doi: 10.1210/en.2018-00317
28
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park. Novel treatments for inflammatory bowel diseaseThe Korean Journal of Internal Medicine 2018; 33(1): 20 doi: 10.3904/kjim.2017.393
29
Patrick P.C. Boor, Petra E. de Ruiter, Patrick S. Asmawidjaja, Erik Lubberts, Luc J.W. van der Laan, Jaap Kwekkeboom. JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfaTranslational Research 2017; 188: 67 doi: 10.1016/j.trsl.2016.11.006
30
Thomas Luger, Masayuki Amagai, Brigitte Dreno, Marie-Ange Dagnelie, Wilson Liao, Kenji Kabashima, Tamara Schikowski, Ehrhardt Proksch, Peter M. Elias, Michel Simon, Eric Simpson, Erin Grinich, Matthias Schmuth. Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agentsJournal of Dermatological Science 2021; 102(3): 142 doi: 10.1016/j.jdermsci.2021.04.007
31
Der-Yuan Chen, Ping-Ning Hsu, Chao-Hsiun Tang, Lindsay Claxton, Satish Valluri, Robert A. Gerber. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in TaiwanJournal of Medical Economics 2019; 22(8): 777 doi: 10.1080/13696998.2019.1606813
32
Fatma Budak, Ahmet Cetinkaya, S. Irem Kaya, Esen Bellur Atici, Sibel A. Ozkan. Sensitive determination and electrochemical evaluation of anticancer drug tofacitinib in pharmaceutical and biological samples using glassy carbon and boron-doped diamond electrodesDiamond and Related Materials 2023; 133: 109751 doi: 10.1016/j.diamond.2023.109751
33
Jeffrey A Lowell, Garvita Sharma, Arun Swaminath, Keith Sultan. Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior ThrombosisInflammatory Bowel Diseases 2024;  doi: 10.1093/ibd/izae100
34
Mark Löwenberg, Geert D’Haens. Next-Generation Therapeutics for IBDCurrent Gastroenterology Reports 2015; 17(6) doi: 10.1007/s11894-015-0444-2
35
Hind M. Almohanna, Marina Perper, Antonella Tosti. Safety concerns when using novel medications to treat alopeciaExpert Opinion on Drug Safety 2018; 17(11): 1115 doi: 10.1080/14740338.2018.1533549
36
Licia Maria Henrique da Mota, Bóris Afonso Cruz, Cleandro Pires de Albuquerque, Deborah Pereira Gonçalves, Ieda Maria Magalhães Laurindo, Ivanio Alves Pereira, Jozélio Freire de Carvalho, Geraldo da Rocha Castelar Pinheiro, Manoel Barros Bertolo, Maria Raquel da Costa Pinto, Paulo Louzada-Junior, Ricardo Machado Xavier, Rina Dalva Neubarth Giorgi, Rodrigo Aires Corrêa Lima. Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinibRevista Brasileira de Reumatologia (English Edition) 2015; 55(6): 512 doi: 10.1016/j.rbre.2015.09.003
37
Hiroaki Hayashi, Ryusuke Kaneko, Shunsuke Demizu, Daichi Akasaka, Manabu Tayama, Takafumi Harada, Hiroki Irie, Yoshio Ogino, Naoko Fujino, Eiji Sasaki. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent ModelsJournal of Pharmacology and Experimental Therapeutics 2018; 366(1): 84 doi: 10.1124/jpet.118.248153